Rationale

Gut microbiota plays an important role in host metabolism. Antipsychotic drugs can result in metabolic abnormalities. Probiotics may ameliorate the antipsychotic drug-induced metabolic abnormalities by regulating gut microbiota.

Objective

To determine whether Bifidobacterium intervention can ameliorate olanzapine-induced weight increase.

Methods

Enrolled patients were assigned to either the olanzapine or olanzapine plus Bifidobacterium group. The following were assessed: body weight, body mass index (BMI), appetite, latency to increased appetite, and baseline weight increase of more than 7%. All assessments were conducted at baseline and at 4, 8, and 12 weeks of treatment.

Results

We enrolled 70 patients with schizophrenia or schizophrenic affective disorder, and 67 completed the study. Treatment for 4 weeks led to between-group differences in weight change (2.4 vs. 1.1 kg, p < 0.05) and BMI (0.9 vs. 0.4, p < 0.05). However, this difference disappeared at 8 and 12 weeks of treatment (both p > 0.05). The two groups did not differ in appetite increase at any time point (p > 0.05). The mean time from olanzapine initiation to appetite increase was also not significantly different between the two groups (t = 1.243, p = 0.220).

Conclusions

Probiotics may mitigate olanzapine-induced weight gain in the early stage of treatment and delay olanzapine-induced appetite increase.

中文翻译：

---

双歧杆菌对奥氮平致精神病患者体重和食欲变化的影响

基本原理

肠道微生物群在宿主代谢中起着重要作用。抗精神病药物可导致代谢异常。益生菌可以通过调节肠道微生物群来改善抗精神病药物引起的代谢异常。

客观的

确定双歧杆菌干预是否可以改善奥氮平引起的体重增加。

方法

纳入的患者被分配到奥氮平或奥氮平加双歧杆菌组。评估了以下内容：体重、体重指数 (BMI)、食欲、食欲增加的潜伏期以及超过 7% 的基线体重增加。所有评估均在基线和治疗 4、8 和 12 周时进行。

结果

我们招募了 70 名患有精神分裂症或精神分裂症情感障碍的患者，其中 67 名完成了研究。4 周的治疗导致体重变化（2.4 与 1.1 公斤，p  < 0.05）和 BMI（0.9 与 0.4，p  < 0.05）的组间差异。然而，这种差异在治疗 8 周和 12 周时消失（均p  > 0.05）。两组在任何时间点的食欲增加均无差异（p  >0.05）。两组之间从奥氮平开始到食欲增加的平均时间也没有显着差异（t  = 1.243，p  = 0.220）。

结论

益生菌可在治疗早期减轻奥氮平引起的体重增加并延迟奥氮平引起的食欲增加。